CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported fourth-quarter profit of $159 million.
On a per-share basis, the Cambridge, Massachusetts-based company said it had net income of $1.50.
The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.87 per share.
The biopharmaceutical company posted revenue of $658.4 million in the period, which beat Street forecasts. Seven analysts surveyed by Zacks expected $640.3 million.
For the year, the company reported profit of $235.2 million, or $2.34 per share. Revenue was reported as $1.9 billion.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SRPT at https://www.zacks.com/ap/SRPT
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。